Journal
TOXICOLOGY LETTERS
Volume 190, Issue 3, Pages 333-339Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.toxlet.2009.03.027
Keywords
DNA adducts; Environmental genotoxins; Mutagenic threshold; Pharmaceutical impurities; Risk assessment; S(N)1 or S(N)2 reactions
Categories
Funding
- American Chemistry Council
- Brain Tumor Society
- Health Effects Institute
Ask authors/readers for more resources
This perspective first considers the potential impact of the Viracept-EMS case in the framework of the current understanding of the low-dose effects of DNA-reactive chemicals and the approaches used to estimate health risks from genotoxins occurring as impurities in pharmaceutical products or as contaminants in the environment or workplace. It also presents an outlook on the nature of additional research building upon the Viracept-EMS case to test assumptions underlying thresholded dose-response relationships and to establish biologically based risk assessment models in lieu of default models for DNA-reactive compounds. (C) 2009 Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available